Cardiology Positron Emission Tomography Scan Market Share and Future Forecast by 2032
Cardiology Positron Emission Tomography Scan Market Share and Future Forecast by 2032
The cardiology positron emission tomography (PET) scan market is witnessing steady growth due to increasing demand for accurate, non-invasive cardiac imaging solutions. PET scans offer superior diagnostic capabilities in detecting coronary artery disease, assessing myocardial viability, and guiding treatment plans. Growing prevalence of cardiovascular disorders, rising geriatric population, and technological advancements in imaging systems—such as hybrid PET/CT and PET/MRI—are key factors propelling market expansion. North America currently leads the market due to well-established healthcare infrastructure and early adoption of advanced diagnostic technologies, while Asia Pacific is emerging rapidly driven by healthcare investments and growing awareness. However, challenges like high equipment costs and limited access to radiopharmaceuticals in certain regions may restrain growth.
According to Fortune Business Insights, the global cardiology positron emission tomography (PET) scan market size was valued at USD 1.91 billion in 2024. The market is projected to grow from USD 1.97 billion in 2025 to USD 2.56 billion by 2032, exhibiting a CAGR of 3.8% during the forecast period. North America dominated the cardiology positron emission tomography scan market with a market share of 55.49% in 2024.
RadNet, Inc. (U.S.)
Sonic Healthcare Limited (Australia)
Akumin Inc. (U.S.)
Apex Radiology (Australia)
Alliance Medical Limited (U.K.)
Novant Health (U.S.)
InHealth Group (U.K.)
Dignity Health (U.S.)
Concord Medical (China)
Siemens Healthcare Limited (Germany)
Mediworks (China)
In April 2025, Southcoast Health (U.S.) announced the launch of new imaging suites offering advanced PET/CT scans for neurology, oncology, and cardiology at their facilities. This reflects growing demand for integrated imaging services leveraging combined anatomical and metabolic data with greater diagnostic precision.
Aging Population & Cardiovascular Disease Burden: Increasing prevalence of coronary artery disease (CAD) and myocardial infarction elevates demand for detailed cardiac imaging to guide treatment.
Advances in Radiopharmaceuticals: In September 2024, FDG injection Flyrdicado (flurpiridaz F‑18) won FDA approval for myocardial perfusion imaging, enhancing image clarity for ischemic heart disease.
Rise of Hybrid Imaging Systems: The adoption of PET/CT and PET/MRI systems supports simultaneous anatomical and functional imaging—accurately measuring coronary flow reserve, myocardial perfusion, and disease viability.
Automation & AI: Advanced integration of automation modules and AI-driven analysis enhances diagnostic precision and operational efficiency.
High Setup & Operating Costs: PET scanners, tracers, and cyclotrons remain capital-intensive, limiting adoption, especially in price-sensitive regions.
COVID-19 Backdrop: The pandemic caused a temporary 64% drop in cardiology-related imaging from April 2019 to April 2020 according to the IAEA, with resource shifts and lockdowns hampering market growth.
Regulatory & Reimbursement Complexities: Approval pathways for radiopharmaceuticals and variable payer systems can slow technology rollouts.
The Fortune Business Insights market report provides segment-wise analysis covering:
Source of payment: public insurance, private insurance, and out-of-pocket
Service provider: hospitals, diagnostic centers, others
Region-specific growth forecasts (North America, Europe, Asia-Pacific, etc.)
Major imaging providers—like Sonic Healthcare, Apex Radiology, and Alliance Medical—are growing through both organic expansion and strategic acquisitions. Investments focus on adding hybrid PET/CT suites, integrating AI software, and signing partnerships for tracer access (e.g., IONETIX's cooperation with Provision Diagnostic Imaging in Feb 2024).
Hybrid Imaging Dominance: Combined PET/CT and PET/MRI systems dominate due to precise visualization of coronary flow reserve and myocardial perfusion.
Automated & AI-enabled Workflows: Improved efficiency through software-driven lesion detection and scan quantification.
New Tracers & Radiopharmaceuticals: F‑18 flurpiridaz offers better distribution compatibility—shorter half-life and improved image fidelity.
North America leads the global market, holding approximately USD 1.06 billion in 2024. This leadership stems from robust infrastructure, reimbursement frameworks, and early adoption.
Europe maintains significant share via widespread PET/CT deployment and growing AI and tracer capabilities.
Asia‑Pacific is set to outpace other regions in CAGR due to expanding healthcare infrastructure, rising cardiology cases, and improving healthcare access.
Latin America, MEA - Gradual uptake in hybrid imaging expected as access expands in urban centers, though infrastructure remains uneven.
Explore the full research report with detailed insights and TOC:https://www.fortunebusinessinsights.com/cardiology-positron-emission-tomography-scan-market-113310
The cardiology PET scan market is poised for continued, albeit moderate, growth through 2032. Its expansion will be supported by several factors:
Wider deployment of hybrid imaging (PET/CT, PET/MRI) in community hospitals.
Next-gen radiotracers like F‑18 flurpiridaz simplifying tracer logistics and increasing tract usage.
Sophisticated AI-based diagnostic tools advancing scan interpretation and resource use.
Proactive cardiac screening and early detection protocols for CAD emphasizing PET.
Emerging partnerships—like IONETIX‑Provision—streamlining isotope availability.
The cardiology PET scan market is entering a mature growth phase—balancing core demand from cardiovascular disease monitoring with innovations in imaging hardware, tracer chemistry, and automation. Key players like RadNet, Sonic Healthcare, Siemens, and Mediworks are capitalizing on this trend, deploying next-gen technologies and geographic expansion. As the market grows from $1.91 billion in 2024 to $2.56 billion by 2032, stakeholders across the value chain—from imaging centers to software developers—stand to benefit.
About Us:
Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free),
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com